Results 11 to 20 of about 60,441 (347)

Medications for opioid use disorder shape immune responses during chronic HIV infection [PDF]

Cell Reports Medicine
Summary: People living with HIV (PLWHs) have higher risk of opioid use disorder (OUD). Whether medications for opioid use disorder (MOUDs) change immune responses in HIV infection is unknown.
Jack A. Collora, Savannah F. Steinhauser, Timothy C. Davenport, Daniel C. Lin, Amare Eshetu, Samana Zeidi, Rachel Kim, Cynthia Frank, Yuval Kluger, Sandra A. Springer, Ya-Chi Ho   +10 more
doaj   +2 more sources

Availability of Medications for Opioid Use Disorder in US Psychiatric Hospitals.

JAMA Netw Open
This cross-sectional study examines the availability of medications for opioid use disorder in psychiatric hospitals in the US.
Cohen SM, Beetham T, Fiellin DA, Muvvala SB.   +3 more
europepmc   +3 more sources

Concurrent opioid and alcohol withdrawal management [PDF]

Mental Health Clinician, 2023
Concurrent alcohol and opioid withdrawal syndrome is a common and challenging clinical scenario with little published evidence or guidance to inform pharmacotherapy strategies.
Michelle Colvard, PharmD, BCPP
doaj   +1 more source

Use of Medications for Opioid Use Disorder and Child Welfare Outcomes.

JAMA Health Forum
This cohort study investigates whether use of medications for opioid use disorder in pregnancy is associated with higher rates of infants discharge home with their mothers after birth.
Muhar A, McNeer E, Presley LD, Morad A, Loch SF, Dupont WD, Patrick SW.   +6 more
europepmc   +3 more sources

Medication-Assisted Treatment for Opioid-Use Disorder [PDF]

Mayo Clinic Proceedings, 2019
The United States is in the midst of a national opioid epidemic. Physicians are encouraged both to prevent and treat opioid-use disorders (OUDs). Although there are 3 Food and Drug Administration-approved medications to treat OUD (methadone, buprenorphine, and naltrexone) and there is ample evidence of their efficacy, they are not used as often as they
Tyler S. Oesterle, Nuria J. Thusius, Teresa A. Rummans, Mark S. Gold   +3 more
openaire   +4 more sources

Attending a Biopsychosocially Focused Buprenorphine Training Improves Clinician Attitudes

Frontiers in Psychiatry, 2021
Objective: Substance use disorders remain highly stigmatized. Access to medications for opioid use disorder is poor. There are many barriers to expanding access including stigma and lack of medical education about substance use disorders. We enriched the
Holly Ann Russell, Brian Smith, Mechelle Sanders, Elizabeth Loomis   +3 more
doaj   +1 more source

Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort

Drug and Alcohol Dependence Reports, 2023
Background: Research gaps exist on the use of medications for opioid use disorder (OUD) among birthing people. Methods: This retrospective cohort study included people who underwent childbirth deliveries during 2017-2020 and had a diagnosis of OUD ...
Xi Wang, Zachary Meisel, Katherine Kellom, Jennifer Whitaker, Douglas Strane, Anyun Chatterjee, Rebecka Rosenquist, Meredith Matone   +7 more
doaj   +1 more source

Medications Development for Treatment of Opioid Use Disorder [PDF]

Cold Spring Harbor Perspectives in Medicine, 2020
This review describes methods for preclinical evaluation of candidate medications to treat opioid use disorder (OUD). The review is founded on the propositions that (1) drug self-administration procedures provide the most direct method for assessment of medication effectiveness, (2) procedures that assess choice between opioid and nondrug reinforcers ...
E. Andrew Townsend, S. Stevens Negus, Matthew L. Banks   +2 more
openaire   +2 more sources

Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study

Addiction Science & Clinical Practice, 2022
Background Residential treatment is a common approach for treating opioid use disorder (OUD), however, few studies have directly compared it to outpatient treatment.
Daniel M. Hartung, Sheila Markwardt, Kirbee Johnston, Jonah Geddes, Robin Baker, Gillian Leichtling, Christi Hildebran, Brian Chan, Ryan R. Cook, Dennis McCarty, Udi Ghitza, P. Todd Korthuis   +11 more
doaj   +1 more source

A conceptual framework for how structural changes in emerging acute substance use service models can reduce stigma of medications for opioid use disorder

Frontiers in Psychiatry, 2023
Stigma toward people taking medication for opioid use disorder (MOUD) is prevalent, harmful to the health and well-being of this population, and impedes MOUD treatment resource provision, help-seeking, and engagement in care.
Timothy D. Becker, Timothy D. Becker, Evan L. Eschliman, Ashish P. Thakrar, Lawrence H. Yang, Lawrence H. Yang   +5 more
doaj   +1 more source